In the following video, Motley Fool health care analyst Brenton Flynn discusses Bausch & Lomb and the scuttlebutt surrounding a potential acquirer. He talks about Abbott Labs (NYSE:ABT), Johnson & Johnson (NYSE:JNJ), Sanofi (NYSE:SNY), Pfizer (NYSE:PFE), and Merck (NYSE:MRK), and just how realistic this purchase would be for each. He also gives his bet on which company, in the end, may be the buyer.
Brenton Flynn has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Mellanox Technologies (MLNX) Q4 2017 Earnings Conference Call Transcript
MLNX earnings call for the period ending December 31, 2017.
Why Intel Corp. Should Make This Processor
This Fool agrees with an industry analyst's desire for Intel to release this chip.
3 Stocks That Feel Like Netflix in 2002
Netflix has turned thousands into millions. Could these three companies do the same?